Posted On: 02/11/2016 11:09:02 AM
Post# of 72446
This is from 2010. Basically Sanofi writes a 400 million dollar check for 2 PRECLINICAL drugs that attempt to do what Kevetrin, a safe clinical drug does.
P.S. Sanofi manufacturers docetaxel.
http://www.fiercebiotech.com/story/sanofi-ink...2010-06-04
"Mel Sorensen, president and CEO of Ascenta. "Restoring tumor suppressor function through the inhibition of the HDM2-p53 interaction offers the potential to control and prevent cancer progression."
P.S. Sanofi manufacturers docetaxel.
http://www.fiercebiotech.com/story/sanofi-ink...2010-06-04
"Mel Sorensen, president and CEO of Ascenta. "Restoring tumor suppressor function through the inhibition of the HDM2-p53 interaction offers the potential to control and prevent cancer progression."
(0)
(0)
***On 02/26/2016 at 8:33 am Scottsmith admited to posting under 5 aliases but his post was subsequently deleted. I have a screen shot and will email it to anyone interested.
